Sichuan Kelun Pharmaceutical (002422.SZ): Rosuvastatin Patch Receives Drug Registration Approval

Sichuan Kelun Pharmaceutical (002422.SZ) announced that its chemical drug "Rotigotine Patch" recently received drug registration approval from the National Medical Products Administration. The Rotigotine Patch was developed by UCB Pharma, approved by the EU in 2006, approved for import in China in 2018, and used for monotherapy of early-stage idiopathic Parkinson's disease symptoms and signs, or in combination with levodopa for various stages of the disease.